On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

High blood pressure isn’t classified as heart disease, but it plays a crucial role in the development of heart disease and ...

A new drug may help protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the ...